{"product_id":"lilly-business-model-canvas","title":"Eli Lilly Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a leading pharma strategic playbook with a concise Business Model Canvas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Eli Lilly’s strategic playbook with a concise Business Model Canvas that maps its value propositions, key partners, and revenue engines across R\u0026amp;D, Rx commercialization, and global supply chains. This snapshot reveals growth levers and strategic risks; purchase the full, editable canvas to benchmark, model scenarios, and apply industry-grade insights to your investment or strategic plan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborate with academic and research institutions on early-stage discovery, target validation, and translational science to de‑risk candidates and speed entry to clinic. Access cutting-edge platforms, disease models, and clinical expertise housed at leading centers, leveraging ecosystem funding such as the ~49 billion USD NIH budget in 2024 for translational grants. Share risk and accelerate proof‑of‑concept through joint grants and publications, and build talent pipelines and visibility in priority therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Alliances and Co-development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eForm strategic alliances to in-license assets and co-develop novel modalities, leveraging Lilly’s 2024 R\u0026amp;D-led scale to accelerate candidates into late-stage trials. Combine Lilly’s development, regulatory, and commercial reach with biotech innovation to share risk and speed time-to-market. Structure deals with upfronts, milestone payments, and royalties tied to approvals and sales, aligning incentives. Expand pipeline optionality across diabetes, oncology, immunology, neuroscience, and cardiovascular.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs, CMOs, and Technology Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly outsources clinical operations, data management, and specialized manufacturing to CROs, CMOs and tech vendors, tapping a CRO market that exceeded $60 billion in 2024 to scale global trials rapidly. These partners provide flexible capacity and speed while advanced manufacturing and analytics platforms drive quality, scalability and cost-efficiency across production. Integrated digital tools (EHR-linked capture, cloud analytics, eCOA, eConsent) ensure real-time data, traceability and regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly engages proactively with FDA and EMA to secure approvals and safety alignment, leveraging FDA priority review (6-month goal) and EMA centralized review (~210 days).\u003c\/p\u003e\n\u003cp\u003eTeams align on trial design, endpoints and post-marketing commitments including REMS\/confirmatory trials to meet regulator expectations.\u003c\/p\u003e\n\u003cp\u003eMaintain 24\/7 pharmacovigilance, submit PSURs\/PSUR-equivalents and support accelerated\/priority pathways for high unmet needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory timelines: FDA 6 months, EMA ~210 days\u003c\/li\u003e\n\u003cli\u003eSafety: 24\/7 signal detection, PSURs\u003c\/li\u003e\n\u003cli\u003ePost-market: REMS\/confirmatory trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, Providers, and Patient Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner with payers, providers, and patient advocacy to demonstrate clinical and economic value for reimbursement, co-create outcomes-based agreements and access programs, and embed patient voices into trial design and education to strengthen provider adoption via robust evidence and real-world data; Eli Lilly reported $40.8B revenue in 2023 and continued heavy 2024 investment in R\u0026amp;D and outcomes research.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue-based contracts\u003c\/li\u003e\n\u003cli\u003eAccess programs\u003c\/li\u003e\n\u003cli\u003ePatient-centered trials\u003c\/li\u003e\n\u003cli\u003eReal-world evidence for adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerate therapeutics via academia, CRO\/CMO alliances and regulator-payer alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborate with academic and research centers for discovery and translational science, leveraging NIH ~49 billion USD budget in 2024 for grants.\u003c\/p\u003e\n\u003cp\u003eForm strategic alliances and in‑licensing with biotechs, outsourcing to a CRO\/CMO market \u0026gt;60 billion USD in 2024; Lilly reported $40.8B revenue in 2023.\u003c\/p\u003e\n\u003cp\u003ePartner with regulators (FDA priority review ~6 months, EMA centralized ~210 days) and payers for value‑based contracts and access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eDiscovery\/validation\u003c\/td\u003e\n\u003ctd\u003eNIH ~$49B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/CMOs\u003c\/td\u003e\n\u003ctd\u003eTrials\/manufacturing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$60B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/Regs\u003c\/td\u003e\n\u003ctd\u003eAccess\/approval\u003c\/td\u003e\n\u003ctd\u003eFDA 6m, EMA ~210d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Eli Lilly outlining its nine blocks—key partners, activities, resources, value propositions, customer segments, channels, customer relationships, cost structure, and revenue streams—reflecting real-world pharmaceutical R\u0026amp;D, manufacturing, and global commercialization. Ideal for investors and analysts, it includes competitive advantages, SWOT-linked insights, and strategic implications for decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Eli Lilly’s complex pharma strategy into a single editable canvas to quickly align R\u0026amp;D, regulatory, partnerships, and commercial execution. Great for fast-boardroom reviews, team collaboration, and saving hours on structuring strategic insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscovery and Preclinical Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIdentify targets and optimize leads using integrated biology and chemistry platforms, advancing candidates through lead optimization and translational assays. Generate preclinical efficacy, safety and PK\/PD data to de-risk candidates before IND filings, supporting regulatory clearance. Lilly sustains multibillion-dollar R\u0026amp;D investment (about $9 billion in 2024) to build a diversified, high-quality pipeline across oncology, immunology, diabetes and neuroscience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Medical Affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execute Phase I–III and post-marketing studies across hundreds of ongoing programs in 2024, aligning endpoints to regulatory and payer requirements. Engage KOLs and advisory boards to refine evidence plans and publish peer‑reviewed results to educate HCPs. Generate real‑world evidence to support access and lift adoption, informing pricing and formulary discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, Quality, and Safety Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly manages global regulatory submissions and interactions with agencies including the FDA and EMA, coordinating filings and reviews throughout 2024. The company enforces GMP, GCP and GLP standards across manufacturing and clinical operations. Pharmacovigilance teams monitor safety signals and deploy risk mitigation plans. Lifecycle compliance processes ensure timely labeling updates and post‑approval commitments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly scales production across small molecules, biologics, and injectables while securing raw materials and managing cold-chain logistics to protect biologics stability. The company focuses on yield, cost and reliability optimization across internal plants and CMOs, and enacts redundancy and continuity plans to mitigate supply disruptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale: small molecules, biologics, injectables\u003c\/li\u003e\n\u003cli\u003eSupply: raw materials, cold chain\u003c\/li\u003e\n\u003cli\u003eOptimize: yields, cost, reliability\u003c\/li\u003e\n\u003cli\u003eResilience: redundancy, continuity planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEli Lilly plans launches, pricing, and reimbursement strategies centrally, aligning launch sequencing to maximize uptake of growth drivers like GLP-1\/tirzepatide franchises while targeting payer formularies and tenders across markets.\u003c\/p\u003e\n\u003cp\u003eSales, marketing, and patient support services are deployed regionally with heavy investment in specialty channels and hub services to secure access and adherence; 2024 R\u0026amp;D spend ~6.7B supported lifecycle and indication expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLaunch planning\u003c\/li\u003e\n\u003cli\u003ePricing \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003ePayer \u0026amp; tender negotiations\u003c\/li\u003e\n\u003cli\u003eSales, marketing, patient support\u003c\/li\u003e\n\u003cli\u003eBrand lifecycle \u0026amp; indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDe-risking hundreds of programs with \u003cstrong\u003e$9B\u003c\/strong\u003e R\u0026amp;D and integrated biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIdentify targets and optimize leads via integrated biology\/chemistry, advancing hundreds of programs and investing about $9B R\u0026amp;D in 2024 to de-risk pipeline. Execute Phase I–III and post‑marketing studies, real‑world evidence and KOL engagement to secure approvals and payer access. Scale manufacturing across small molecules, biologics and injectables with cold‑chain, CMOs and redundancy to protect supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003ehundreds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Eli Lilly Business Model Canvas previewed here is the actual document, not a mockup, showcasing value propositions, key partners, revenue streams and cost structure specific to Lilly. When you purchase, you’ll receive this same complete, editable file ready for presentation and analysis. No substitutions or fillers—what you see is what you’ll download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162350104953,"sku":"lilly-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/lilly-business-model-canvas.png?v=1762699417","url":"https:\/\/portersfiveforce.com\/products\/lilly-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}